九州娱乐城

Share Price:

APNASPEN九州娱乐城 Pharmacare Hldgs162780 (0.00%)

九州娱乐城 will be in a closed period from 1 January 2025 until the publication of the Interim Results on the JSE SENS platform on 3 March 2025.

九州娱乐城 announces local availability of Lilly鈥檚 Mounjaro

Stephen Saad, 九州娱乐城 Group Chief Executive

九州娱乐城 has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro庐, a therapeutic option available to physicians for the treatment of Type II diabetes.

九州娱乐城 and SEMDSA highlight the alarming rise of non-communicable diseases on World Diabetes Day

Heinz Sch眉tte, 九州娱乐城 Pharmacare Regional CEO, Dr Reyna Daya, SEMDSA President & Endocrinologist, and Stavros Nicolau, 九州娱乐城 Group Senior Executive Strategic Trade

九州娱乐城 and SEMDSA earlier today raised awareness around the alarming rise of non-communicable diseases, particularly diabetes, in recognition of World Diabetes Day.

Closed Period

九州娱乐城 is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.